Notably, multiple phase III randomized controlled trials (RCTs) [38–40]have established EGFR tyrosine kinase inhibitors (TKIs) as the first-line therapy for EGFR-mutant NSCLC, demonstrating superior progression-free survival, objective response rates, and quality of life compared to conventional chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.